AI drug discovery aging research · news_exa
AI pinpoints new anti-aging drug candidates
By news_exa · just now
TL;DR: AI-discovered drugs successfully extended the lifespan of lab organisms by over 70%.
Scripps Research scientists have utilized AI to identify novel drug candidates that combat the biological aging process. In testing, over 70% of the AI-selected compounds successfully extended the lifespan of C. elegans, showing remarkable precision. This breakthrough suggests we are nearing a future where software can reliably predict the most effective life-extending therapies.
AI drug discovery aging research · news_exa
Transposon Therapeutics’ TPN-101 to be Studied for
By Transposon Therapeutics, Inc · 1d ago
TL;DR: ARPA-H grants $22M to Transposon to develop TPN-101 for healthy aging.
Transposon Therapeutics has secured a $22 million award from ARPA-H to investigate its lead candidate, TPN-101, for its potential to extend healthy human lifespan. The funding supports the PROSPR program, focusing on slowing the biological aging process to prevent age-related diseases. This represents a major federal investment into the rapidly maturing field of longevity science.
AI drug discovery aging research · news_exa
AI could unlock new cystic fibrosis protein target - EMJ GOLD
By Meetal Jotangia · 1d ago
TL;DR: AI identifies a novel protein target for potential new cystic fibrosis treatments.
Researchers are leveraging artificial intelligence to identify a promising new protein target for cystic fibrosis treatment. By scanning complex biological data, AI is uncovering therapeutic pathways that were previously hidden from traditional research methods. This breakthrough could lead to next-generation therapies for patients who don't respond to current standard-of-care treatments.
AI drug discovery aging research · news_exa
AI and The End of Aging
By news_exa · just now
TL;DR: Hevolution Foundation claims AI will turn aging into a solvable engineering challenge.
The Hevolution Foundation suggests that AI is poised to end the 'inevitable decline' of the human body. By rewriting the narrative of aging, the foundation is funding AI initiatives to move past traditional symptom management into regenerative territory. It frames the end of aging not as a fantasy, but as a solved engineering problem.
AI drug discovery aging research · news_exa
AI screens over 1 billion compounds to uncover new anti- ...
By news_exa · just now
TL;DR: New AI platform screens 1 billion compounds to find potential anti-aging protectors.
Researchers at the Indraprastha Institute of Information Technology have launched AgeXtend, a platform that screened 1 billion compounds for anti-aging potential. The explainable AI system doesn't just find molecules; it predicts toxicity and explains how they might slow biological decay. This massive scale of digital screening drastically reduces the time and cost of longevity drug development.
AI drug discovery aging research · news_exa
Study signals a first in drug discovery: AI can tackle aging's ...
By news_exa · just now
TL;DR: AI systems now capable of managing the massive complexity of biological aging.
A landmark study published via EurekAlert! signals that AI can finally handle the 'true complexity' of human aging. Unlike previous narrow models, this new approach tackles multiple biological pathways at once, mirroring the entangled reality of human decay. This holism is a critical step toward creating effective longevity cocktails for humans.
AI drug discovery aging research · news_exa
AI shows promise in fighting antibiotic resistance, but there's a catch | STAT
By Cesar de la Fuente-Nunez, Henry Skinner · 19h ago
TL;DR: AI helps find new antibiotics, but economic hurdles still block global progress.
AI is increasingly being utilized to discover new molecular structures to combat antibiotic-resistant 'superbugs.' However, experts warn that technological breakthroughs alone cannot solve the crisis without significant changes to economic incentives for drug development. This highlights the growing tension between rapid AI innovation and the stagnant business models of the pharmaceutical industry.
AI drug discovery aging research · news_exa
CDI Labs' Dr Tyler Hulett Ph.D. joins global Cancer Grand Challenges team taking on the cancer avoidance challenge
By CDI LABORATORIES, INC. · 1d ago
TL;DR: Global team receives $25M award to investigate biological cancer avoidance.
Dr. Tyler Hulett of CDI Labs has joined a global Cancer Grand Challenges team awarded $25 million to solve the mystery of cancer avoidance. The interdisciplinary group will investigate why some cells remain healthy despite carrying mutations that should trigger disease. This research could shift the oncology focus from late-stage treatment to preemptive biological prevention.
AI drug discovery aging research · news_exa
Annovis CEO eyes spring breakthrough for Alzheimer’s drug - Longevity.Technology
By Kyle Umipig · 1d ago
TL;DR: Annovis CEO expects imminent clinical breakthrough for its lead Alzheimer’s drug.
Annovis Bio is nearing a significant regulatory milestone with its Alzheimer’s drug candidate, buntanetap, as late-stage trials progress. The company’s CEO anticipates a spring breakthrough that could pave the way for FDA submission, targeting the underlying causes of neurodegeneration. Investors and patients alike are watching closely for the data readout expected this season.
AI drug discovery aging research · news_exa
Incregen Therapeutics Selected for Leading Healthcare Innovation Program
By Incregen Therapeutics · 1d ago
TL;DR: Incregen joins Mayo Clinic program to accelerate obesity and metabolic disease treatments.
Incregen Therapeutics has been selected to join the Mayo Clinic Berg Innovation Exchange, a prestigious program for healthcare innovators. The company is developing novel therapies for obesity and metabolic diseases, which remain high-priority areas for clinical development. This partnership will provide Incregen with specialized resources and expertise to accelerate its metabolic pipeline.
AI drug discovery aging research · news_exa
Liquid AI and Insilico Launch LFM2-2.6B-MMAI: Lightweight Model for On-Premise Drug Discovery - GeneOnline News
By Steven Chung · 1d ago
TL;DR: Liquid AI and Insilico launch a lightweight, on-premise model for private drug discovery.
Liquid AI and Insilico Medicine have unveiled LFM2-2.6B-MMAI, a compact model specifically designed for on-premise drug discovery. This collaboration addresses data privacy concerns by allowing biotech firms to run powerful AI locally rather than in the cloud. It marks a significant shift toward accessible, high-performance computing in sensitive laboratory environments.
AI drug discovery aging research · news_exa
Leveraging AI to identify dual-purpose aging and disease ...
By Alex Zhavoronkov · just now
TL;DR: AI targets dual-purpose therapies to treat both aging and chronic disease simultaneously.
Scientists are leveraging AI to identify 'dual-purpose' drugs that simultaneously target chronic diseases and the aging process itself. By focusing on genes like age-1, researchers aim to hit two birds with one stone: slowing systemic decline while preventing specific pathologies. This strategy could redefine preventive medicine for the elderly.
AI drug discovery aging research · news_exa
iLoF and Industry Leader Bluepharma Announce Strategic Collaboration to Deploy AI-Powered Optomics® for Faster Drug Development and to Advance the Future of Personalised Medicine
By iLoF · 1d ago
TL;DR: iLoF and Bluepharma partner to use AI for faster personalized drug discovery.
iLoF and Bluepharma have entered a strategic partnership to integrate the AI-powered Optomics platform into drug development workflows. The collaboration aims to accelerate the creation of personalized medicines by leveraging optical fingerprints and advanced data analytics. By streamlining clinical trials, the duo hopes to bring more targeted therapies to market faster.
AI drug discovery aging research · news_exa
BrYet US, Inc. Files IND Application for ML-016, Lead Oncology Therapeutic for Advanced Solid Tumors with Lung and/or Liver Metastases - The Abilene Reporter-News
By Bryet US Inc · 1d ago
TL;DR: BrYet files IND for oncology drug targeting lung and liver metastases.
BrYet US has officially filed an Investigational New Drug (IND) application for ML-016, a novel therapeutic targeting advanced solid tumors. The treatment focuses specifically on cancers that have metastasized to the lungs and liver, where treatment options are currently limited. This filing marks a critical transition for the company from preclinical research to human clinical trials.
AI drug discovery aging research · news_exa
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
By Hoth Therapeutics, Inc. · 1d ago
TL;DR: Hoth Therapeutics adopts OpenAI to speed up orphan drug development and regulatory filings.
Hoth Therapeutics is integrating OpenAI's API to accelerate the development of its HT-KIT oncology program for rare cancers. The AI integration will support IND preparation and Phase 1 clinical trial progression, streamlining complex regulatory and research workflows. This move highlights the growing trend of biopharma companies using GenAI to fast-track orphan drug designations.
AI drug discovery aging research · news_exa
Deep learning and generative artificial intelligence in aging ...
By news_exa · just now
TL;DR: Researchers are moving from treating individual diseases to managing biological aging with AI.
A comprehensive review hosted by the NIH examines how deep learning and generative AI are revolutionizing healthy longevity medicine. The research highlights the transition from treating age-related diseases to proactively managing the aging process itself using neural networks. This shift represents a fundamental change in how the medical establishment views human lifespan.
AI drug discovery aging research · news_exa
Artificial Intelligence & Technology Collaboratory for Aging ...
By news_exa · just now
TL;DR: Johns Hopkins launches major AI collaboratory to improve health for older adults.
The Johns Hopkins AITC is a federally funded resource dedicated to merging engineering expertise with clinical care for older adults. By building a massive infrastructure for AI research, they aim to develop technologies that improve well-being beyond just lifespan extension. This demonstrates significant institutional and government backing for AI-powered geriatrics.
AI drug discovery aging research · news_exa
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgenc - 04.03.2026
By news_exa · 1d ago
TL;DR: KALA BIO launches private AI infrastructure for secure drug discovery.
KALA BIO has launched a strategic initiative to develop an on-premises AI infrastructure specifically for biotech research applications. Through an exclusive license for the 'Researgenc' platform, the company aims to secure proprietary data while accelerating drug discovery. This move signals a trend toward biotech firms building internal, private AI ecosystems rather than relying on public clouds.
AI drug discovery aging research · news_exa
Longevity science is on the cusp of major breakthroughs ...
By Alexei Oreskovic · just now
TL;DR: Experts warn that missing biological data is slowing AI-driven longevity breakthroughs.
Fortune reports that while longevity science is on the verge of massive breakthroughs, significant ‘data gaps’ remain a primary hurdle. Experts emphasize that AI’s predictive power is only as good as the biological datasets used to train it. Bridging these gaps is now the top priority for major players like Hevolution and Insilico Medicine.
AI drug discovery aging research · news_exa
Contact - Observer-Reporter
By By:
KALA BIO, Inc. via
GlobeNewswire · 1d ago
TL;DR: KALA BIO advances proprietary AI platform to streamline biotech research.
KALA BIO is expanding its technological footprint by developing 'Researgenc,' a proprietary AI research platform designed for the biotech industry. The initiative focuses on creating a secure, localized AI environment to manage complex biological data. This strategic shift highlights the increasing necessity of bespoke AI tools for high-stakes pharmaceutical research.
AI drug discovery aging research · news_exa
Towards AI-driven longevity research: An overview
By news_exa · just now
TL;DR: A new roadmap outlines how AI will dominate longevity research in the coming decade.
A review in Frontiers in Aging provides a high-level overview of the transition toward AI-driven longevity interventions. The article summarizes current methodologies and highlights how machine learning analyzes complex aging variables that humans simply cannot track. It serves as a foundational roadmap for the next decade of longevity research.
AI drug discovery aging research · news_exa
Iowa City Press-Citizen - Home
By news_exa · 19h ago
TL;DR: LunaI Bioworks launches Transformer-based AI platform to speed up drug discovery.
LunaI Bioworks has unveiled a new Transformer-based platform designed to secure generative AI and accelerate drug discovery. This corporate unveiling points toward the industrial scale-up of AI tools in the pharmaceutical sector. While the notice is localized to Iowa City, the implications for rapid drug development are global.